Dyadic International, Inc. (DYAI) News
Filter DYAI News Items
DYAI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DYAI News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest DYAI News From Around the Web
Below are the latest news stories about DYADIC INTERNATIONAL INC that investors may wish to consider to help them evaluate DYAI as an investment opportunity.
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare ConferenceJUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, provided an update on its business development efforts related to its Alternative Proteins business and emerging interest i |
Dyadic International And 2 Other US Penny Stocks To WatchThe U.S. stock market recently experienced a significant downturn, with major indices like the Dow Jones Industrial Average and the S&P 500 suffering their worst one-day losses in months due to concerns over interest rate policies. In this context, investors might consider exploring alternative investment areas such as penny stocks, which remain a relevant opportunity despite being considered somewhat niche today. These stocks often represent smaller or newer companies and can offer... |
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform TechnologyGrant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates Foundation for the cell line development of monoclonal antibodies (mAbs) targeting respiratory syncytial virus (RSV) and malaria utilizing the company’s proprietary C1 protein production platform to |
Top US Penny Stocks To Watch In November 2024As the U.S. equities market looks to rebound from last week's downturn, investors are keenly watching for opportunities amidst the shifting landscape. Penny stocks, a term that harks back to earlier days of trading, continue to offer intriguing possibilities for those interested in smaller or newer companies. Despite their modest price points, these stocks can represent significant growth potential when backed by strong financials and solid fundamentals. |
Dyadic International Third Quarter 2024 Earnings: Beats ExpectationsDyadic International ( NASDAQ:DYAI ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.96m (up 393% from... |
DYAI: Milestones Achieved; Product Revenues Next?By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT 3Q:24 Operational & Financial Results Dyadic International Inc. (NASDAQ: DYAI) released third quarter 2024 operational and financial results in a press release on August 13, 2024, filed its Form 10-Q with the SEC and held a conference call with investors. Since the last quarterly update, Dyadic participated in several |
Dyadic International Inc (DYAI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...Despite a net loss, Dyadic International Inc (DYAI) showcases significant revenue growth and promising partnerships in the biopharmaceutical sector. |
Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key MarketsHighlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license fees and milestone payments.Received $1 million milestone payment for animal-free recombinant albumin products.Received $425,000 success fees for achieving production targets in a dairy enzyme collaboration.Expanded recombinant life science protein portfo |
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the third quarter 2024 and host a corporate update conference call on T |
Dyadic International Inc (DYAI) Q2 2024 Earnings Call Highlights: Strategic Positioning Amid ...Despite a drop in quarterly revenue, Dyadic International Inc (DYAI) focuses on expanding its technology and partnerships to unlock future growth opportunities. |